Related Experiment Video
Updated: Jun 9, 2026
10:05
Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins
Published on: August 7, 2014
14.3K
Digging Deeper Into Cardiovascular Plasma Proteomics: Opportunities and Limitations of Current Platforms
Pich Chhay1,2, Owen Tang1,2, Lizhuo Ai3
1Cardiovascular Discovery Group, Kolling Institute of Medical Research, Northern Sydney Local Health District, Australia (P.C., O.T., M.P.G., G.A.F.).
Circulation. Genomic and Precision Medicine
|October 6, 2025
Summary
Proteomics offers new hope for detecting coronary artery disease (CAD) early. This review explores proteomics platforms for discovering novel biomarkers to improve cardiovascular disease risk stratification and patient outcomes.
Area of Science:
- Cardiovascular Research
- Proteomics
- Biomarker Discovery
Background:
- Coronary artery disease (CAD) is a leading global cause of death.
- Despite advances, acute coronary syndromes persist, necessitating better early detection and risk stratification.
- Proteomics presents a promising approach for identifying novel biomarkers in cardiovascular disease.
Purpose of the Study:
- To provide an updated overview of major proteomic platforms for coronary artery disease research.
- To discuss the strengths, limitations, and applications of various proteomics technologies.
- To highlight the potential of proteomics in discovering new biomarkers for early CAD detection and risk assessment.
Main Methods:
- Review of major proteomic platforms and their methodologies.
- Analysis of recent coronary artery disease studies utilizing proteomics.
- Integration of proteomics data with clinical information and other omics disciplines.
Main Results:
- Proteomics enables high-throughput analysis of protein abundance and modifications relevant to cardiovascular disease.
- Low-abundance proteins can be detected, offering insights into cardiac pathophysiology and potential new biomarkers.
- Understanding technology limitations is crucial for effective biomarker discovery.
Conclusions:
- Proteomics holds significant potential for revolutionizing the timely detection and management of coronary artery disease.
- Integrating proteomics with clinical data and other omics enhances understanding and improves risk stratification.
- Rigorous validation in clinical trials is essential for translating biomarker discoveries into clinical practice.
Related Concept Videos
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...